PT-141 Dosage and Reconstitution: What Research Shows

PT-141 (bremelanotide) is typically dosed at 1.75 mg subcutaneously, no more than once every 24 hours. To reconstitute a 10 mg vial, add 2 mL of bacteriostatic water for a concentration of 5 mg/mL, which means a 1.75 mg dose equals 0.35 mL (35 units on a U-100 insulin syringe). PT-141 is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder, but it is not approved for men or for general use.

What Is PT-141 and How Is It Approved?

PT-141, also known as bremelanotide, is a synthetic peptide that activates melanocortin receptors. The FDA approved it in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is not approved for men, for erectile dysfunction, or for recreational use.

The approved dose is 1.75 mg injected subcutaneously in the abdomen or thigh at least 45 minutes before anticipated sexual activity. Do not use more than one dose in 24 hours or more than eight doses per month.

PT-141 Reconstitution and Dosage Basics

A complete guide to pt-141 reconstitution and dosage starts with the vial's concentration. Most research vials contain 10 mg of lyophilized powder. You must add bacteriostatic water (BAC water) to dissolve it. The volume you add determines the concentration, which then determines how many milliliters or syringe units you draw for a 1.75 mg dose.

Step-by-Step Reconstitution

1. Clean the vial stoppers with alcohol swabs.
2. Draw 2 mL of bacteriostatic water into a syringe.
3. Inject the water slowly against the inside wall of the PT-141 vial.
4. Swirl gently; do not shake.
5. Let it dissolve completely; store in the refrigerator.

Concentration and Dosing Table

Below is a pt-141 peptide dosage chart for a 10 mg vial. It shows how much BAC water to add and the corresponding volume for a 1.75 mg dose.

BAC water added	Concentration	1.75 mg dose volume	Units on U-100 syringe
1 mL	10 mg/mL	0.175 mL	17.5 units
2 mL	5 mg/mL	0.35 mL	35 units
3 mL	3.33 mg/mL	0.525 mL	52.5 units
5 mL	2 mg/mL	0.875 mL	87.5 units

PT-141 Dosage Male Research and Clinical Data

Clinical trials in men have tested doses from 1.75 mg to 10 mg. Lower doses (1.75–2.5 mg) had modest effects on erectile function with fewer side effects. Higher doses increased nausea and vomiting. For pt-141 dosage male participants, the 1.75 mg subcutaneous dose is the most common starting point in published studies.

A pt-141 10mg dosage for men is not supported by clinical evidence; that amount refers to a vial size, not a single dose. Never exceed 1.75 mg per injection without medical supervision.

Converting PT-141 Dosage in mL and Syringe Units

Because doses are written in milligrams, researchers often calculate pt-141 dosage in ml before drawing a syringe. Use the formula: volume (mL) = dose (mg) ÷ concentration (mg/mL). For example, with a 5 mg/mL solution, 1.75 mg ÷ 5 = 0.35 mL. On a U-100 insulin syringe, 0.35 mL equals 35 units.

Safety, Side Effects, and Legal Status

Common side effects include nausea, flushing, headache, and injection site reactions. PT-141 can temporarily raise blood pressure and lower heart rate. Do not use it if you have uncontrolled hypertension, cardiovascular disease, or are pregnant. The FDA does not approve PT-141 for men or for research use outside clinical trials. Anyone considering PT-141 should consult a healthcare professional.

PT-141 is a prescription medication (Vyleesi) in the US. Research peptides sold online are not FDA-approved and may be unsafe or impure. Buying or using PT-141 without a prescription is illegal in many states. Researchers should follow institutional guidelines and never use unverified peptides in humans.

Practical Tips and Product Quality

Always use bacteriostatic water rather than sterile water for multi-dose vials, because BAC water contains a preservative that slows bacterial growth. Keep the reconstituted peptide refrigerated at 2–8°C (36–46°F) and protect it from light. Use a new syringe and alcohol swab for every draw to avoid contamination.

Never rely on the markings of a syringe alone; verify the concentration on the vial label. If you are using a 10 mg vial and add 2 mL of water, each 0.1 mL contains 0.5 mg of PT-141. That means a 1.75 mg dose requires 0.35 mL, or 35 units on a U-100 syringe. Write the reconstitution date and concentration on the vial.

Discard the vial if the solution looks cloudy or contains particles. Do not freeze reconstituted PT-141, and do not use it past its beyond-use date. These steps reduce the risk of infection and dosing errors.

Vyleesi is a sterile, single-use autoinjector that delivers 1.75 mg of bremelanotide. Research-grade PT-141 is sold as a lyophilized powder and is not intended for human use. The purity and sterility of research peptides are not guaranteed by the FDA. For any clinical purpose, only the prescription product should be used under medical supervision.

COMMON QUESTIONS

Frequently Asked Questions

What is the typical PT-141 dosage for men?

Clinical studies in men have used doses from 1.75 mg to 10 mg, but 1.75 mg subcutaneously is the most common starting point. Higher doses are linked to more nausea and vomiting. PT-141 is not FDA-approved for men, so any use should be under medical supervision.

How do you reconstitute a 10 mg vial of PT-141?

Add 2 mL of bacteriostatic water to a 10 mg vial for a concentration of 5 mg/mL. Swirl gently—do not shake—until the powder dissolves completely. Refrigerate the reconstituted peptide and use a new syringe for each draw.

How many mL is 1.75 mg of PT-141?

The volume depends on the concentration. With 2 mL of water in a 10 mg vial (5 mg/mL), 1.75 mg equals 0.35 mL or 35 units on a U-100 syringe. With 1 mL of water (10 mg/mL), 1.75 mg equals 0.175 mL or 17.5 units.